Cross-institutional HER2 assessment via a computer-aided system using federated learning and stain composition augmentation

The rapid advancement of precision medicine and personalized healthcare has heightened the demand for accurate diagnostic tests. These tests are crucial for administering novel treatments like targeted therapy. To ensure the widespread availability of accurate diagnostics with consistent standards, the integration of computer-aided systems has become essential. Specifically, computer-aided systems that assess biomarker expression have thrusted through the widespread application of deep learning for medical imaging. However, the generalizability of deep learning models has usually diminished significantly when being confronted with data collected from different sources, especially for histological imaging in digital pathology. It has therefore been challenging to effectively develop and employ a computer-aided system across multiple medical institutions. In this study, a biomarker computer-aided framework was proposed to overcome such challenges. This framework incorporated a new approach to augment the composition of histological staining, which enhanced the performance of federated learning models. A HER2 assessment system was developed following the proposed framework, and it was evaluated on a clinical dataset from National Taiwan University Hospital and a public dataset coordinated by the University of Warwick. This assessment system showed an accuracy exceeding 90% for both institutions, whose generalizability outperformed a baseline system developed solely through the clinical dataset by 30%. Compared to previous works where data across different institutions were mixed during model training, the HER2 assessment system achieved a similar performance while it was developed with guaranteed patient privacy via federated learning. ### Competing Interest Statement This work was supported by JelloX Biotech Inc. through an industry-academia partnership. CHY, YAC, SYC, YHH, YLH, YWL YCL, and YYL are employees of JelloX Biotech Inc. All other authors declare no competing interests.